| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Oruka Therapeutics, Inc. (ORKA) has 8 insiders with recent SEC Form 4 filings, including 2 buys and 8 sells. ORKA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.13M | $73.43M | - | |
| COO | 206.2K | $13.38M | - | |
| Other | 36.1K | $2.35M | -7,000 | |
| Dir | 35.0K | $2.27M | - | |
| Dir | 17.5K | $1.14M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 2, 2017 | Mitchell Daniel J | Director | Buy | 11,000 | $2.71 | $29,810.00 | New | |
| Apr 4, 2017 | Ozeroff Christopher David | S.v.p., General Counsel | Sell | 418 | $2.41 | $1,007.38 | -2.3% | |
| Apr 4, 2017 | Bristow Michael R | Pres. &Chief Executive Offic | Sell | 720 | $2.41 | $1,735.20 | -1.7% | |
| Apr 4, 2017 | Keuer Thomas A | Chief Operating Officer | Sell | 390 | $2.41 | $939.90 | -2.7% | |
| Apr 3, 2017 | Selby Brian L. | VP, Finance | Sell | 1,114 | $2.46 | $2,740.44 | -46.6% | |
| Mar 24, 2017 | Conway Robert E | Director | Buy | 25,000 | $2.59 | $64,750.00 | New | |
| Feb 28, 2017 | Ozeroff Christopher David | S.v.p., General Counsel | Sell | 465 | $2.61 | $1,213.65 | -2.5% | |
| Feb 28, 2017 | Keuer Thomas A | Chief Operating Officer | Sell | 465 | $2.61 | $1,213.65 | -3.1% | |
| Feb 28, 2017 | Bristow Michael R | Pres. &Chief Executive Offic | Sell | 763 | $2.61 | $1,991.43 | -1.8% | |
| Feb 27, 2017 | Selby Brian L. | VP, Finance | Sell | 161 | $2.56 | $412.16 | -6.3% |